Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Pharmacotherapy

Pharmacotherapy

Pharmacotherapy refers to the use of medications or drugs to treat or manage various medical conditions.
It involves the selection, dosage, and administration of pharmacological agents to achieve the desired therapeutic effects and minimize adverse reactions.
Pharmacotherapy plays a crucial role in the management of a wide range of diseases, from chronic conditions like hypertension and diabetes to acute illnesses and infectious diseases.
Effective pharmacotherapuy requires a thorough understanding of pharmacokinetics, pharmacodynamics, and the potential interactions between different medications.
Healthcare professionals, such as physicians, pharmacists, and nurses, work collaboratively to optimize pharmacotherapy for individual patients, considering factors like age, comorbidities, and genetic factors.
The field of pharmacotherapy is constantly evolving, with new drugs and therapies being developed to address unmet medical needs.
Effective pharmacotherapy can significantly improve patient outcomes and quality of life.

Most cited protocols related to «Pharmacotherapy»

1
Identification of Housekeeping Genes
Cited 156 times
Microarray expression data of 13,629 publicly available samples hybridized to Affymetrix HG-U133A and HG-U133 Plus 2.0 GeneChips (Affymetrix, Santa Clara, Ca.) were downloaded from the Gene Expression Omnibus.[14] (link) This set of samples comprises gene expression data of a wide variety of different tissues (e.g. primary patient material, cell lines, diseased as well as normal tissues, stem cells etc.) and varying experimental conditions (e.g. transfected/transduced cells, cytokine stimulated, cells under hypoxic conditions, ultraviolet treated cells, cells treated with chemotherapeutics or non cytotoxic drugs etc.). Probesets that were available on both platforms were converted to official gene symbols, averaging expression values of multiple probesets targeting the same gene. Next, quantile normalization was applied to the log2 transformed expression values.[15] (link) For each gene the CV of the expression was calculated. The CV equals the standard deviation divided by the mean (expressed as a percentage). The CV is used as a statistic for comparing the degree of variation between genes, even if the mean expressions are drastically different from each other.[16] (link) The calculated CVs for all genes were ranked. In addition, the MFC was calculated to reflect the minor variation in expression of those candidate housekeeping genes within the large dataset. For validation 2,543 publicly available mouse samples hybridized to Affymetrix Mouse Genome 430 2.0 GeneChips (Affymetrix) were downloaded from the Gene Expression Omnibus.[14] (link). Again, this validation set comprises a wide variety of different mouse tissues and varying experimental conditions.
Total RNA was extracted with Absolutely RNA Miniprep Kit (Stratagene, Amsterdam, The Netherlands), and reverse-transcribed to cDNA with random hexamer and RevertAidTM M-MuLV Reverse Transcriptase (Fermentas, Burlington, Ontario, Canada) according to the manufacturer's protocols. Table 4 shows primer sequences for RPL27, RPL30, OAZ1, RPL22 and RPS29. The same annealing temperature (i.e. 60 °C) and number of cycles (i.e. 25) was used for all primers. The PCR products were analyzed by electrophoresis in a 1.0% agarose gel.
de Jonge H.J., Fehrmann R.S., de Bont E.S., Hofstra R.M., Gerbens F., Kamps W.A., de Vries E.G., van der Zee A.G., te Meerman G.J, & ter Elst A. (2007). Evidence Based Selection of Housekeeping Genes. PLoS ONE, 2(9), e898.
Full text: Click here
Publication 2007
Cell Lines Cells Cytokine DNA, Complementary Electrophoresis Gene Expression Genes Genetic Diversity Genome Hypoxia Microarray Analysis Moloney Leukemia Virus Mus Oligonucleotide Primers Patients Pharmaceutical Preparations Pharmacotherapy RNA-Directed DNA Polymerase RPL22 protein, human Sepharose Stem Cells Tissues
2
Differential Gene Expression in Lung Cancer Smokers
Cited 88 times
All statistical analyses were accomplished using R program language. Gene expression data were processed and normalized using Bioconductor Affy package, based on the Robust Multichip Average (RMA) method[5] (link) for single-channel Affymetrix chips. All 22,283 probe sets based on RMA summary measure were used in class comparison analyses.
Average linkage hierarchical clustering of samples was based on one minus Pearson correlation as the dissimilarity metric.
An ANOVA analysis adjusting for sex was used to test whether genes were differentially expressed between smoking groups (C/N and F/N), between tumor tissue and non-tumor tissue (T/NT), or by pack years of cigarette smoking. Further analyses adjusted by tumor grade or excluding 6 subjects with emphysema or chronic bronchitis or 3 subjects who received chemotherapy prior to the study were conducted, with essentially unaltered results. For analyses including paired tissues (T/NT tissue samples from the same subjects), a linear mixed effects model was used to account for intra-person correlation.
To limit false positive findings, genes were considered statistically significant if their p-values were less than the stringent threshold of 0.001. Under the null hypothesis of no difference in expression profiles, and considering the analysis of 22,283 probes, we expect that by chance the average number of false positive findings will be ≤23. We used the Benjamini-Hochberg[2] procedure to calculate the False Discovery Rate (FDR). We further restricted significant genes to those which showed at least 1.5 fold ratio of geometric means of expression between two groups. Gene selection based on p<0.001 (two-sided) and fold-change >1.5 are referred to as “stringent criteria”.
The Cox Proportional Hazards model[6] was used to estimate the effect of gene expression changes in C/N on survival from lung cancer in smokers. Of the 74 subjects included in this study (all stages), 34 (22 smokers) were alive, and 40 (32 smokers) were deceased as of May 2007. Among the deceased subjects, 36 died of lung cancer. The remaining 4 (2 smokers) died of other cancers and were censored at time of death in the analysis. The time from lung cancer to death or date of last follow-up was between 28 days and 5.0 years for the deceased subjects, and 3.7 and 5.7 years for the subjects alive in May 2007. The relative risk of gene expression was defined as the hazard ratio associated with one standard deviation change of the expression. Analyses were adjusted for stage, sex, and smoking. Age was similarly distributed across the groups and was not adjusted for in the analysis.
Landi M.T., Dracheva T., Rotunno M., Figueroa J.D., Liu H., Dasgupta A., Mann F.E., Fukuoka J., Hames M., Bergen A.W., Murphy S.E., Yang P., Pesatori A.C., Consonni D., Bertazzi P.A., Wacholder S., Shih J.H., Caporaso N.E, & Jen J. (2008). Gene Expression Signature of Cigarette Smoking and Its Role in Lung Adenocarcinoma Development and Survival. PLoS ONE, 3(2), e1651.
Full text: Click here
Publication 2008
6H,8H-3,4-dihydropyrimido(4,5-c)(1,2)oxazin-7-one Bronchitis, Chronic DNA Chips Emphysema Gene Expression Genes Genetic Selection Lung Cancer Malignant Neoplasms Neoplasms neuro-oncological ventral antigen 2, human Pharmacotherapy Tissues
3
Tumor Mutational Burden and Immune Checkpoint Inhibitor Outcomes
Cited 87 times
The total number of somatic mutations identified was normalized to the exonic coverage of the respective MSK-IMPACT panel in megabases. Mutations in driver oncogenes were not excluded from the analysis. Overall survival analysis on ICI patients was performed from the date of first infusion of any ICI. For patients who received multiple courses of ICI, the first treatment was used for analysis.Patients were censored at the date of last attended appointment at MSK if death was not recorded in the electronic medical record.
For analysis of patients who did not receive ICI, all patients for whom MSK-IMPACT data was available across all histologies were included. Overall survival analysis was performed from the date of first infusional chemotherapy.
Survival analysis was performed using Kaplan Meier with log-rank p values reported. Multivariable analysis was performed using Cox proportional hazard regression with inclusion of variables significant on univariate regression including normalized TMB, cancer type, age, ICI drug class , and year of ICI administration. Year of ICI administration was included in order to avoid any possible differences in patients treated in the early years of MSK-IMPACT testing being available.
For each histology, we subsequently identified cases in the top 20% percentile of TMB and determined the log-rank p-value for difference in OS and the direction of the effect with a HR determined from a coxph model. Additional analyses were performed with the TMB cutoff ranging from 10 to 50%, as well as with the TMB cutoff instead defined among all patients (both ICI-treated and non-ICI-treated).
Response data for individual histologies was obtained from published analyses of clinical outcome in the cohorts of patients with NSCLC or esophagogastric cancer patients.15 (link),16 (link). For patients with head and neck cancer, radiology records were reviewed manually to determine evidence of progression or tumor response. In these tumor types, clinical benefit was defined as any partial/complete response, or evidence of stable disease for ≥6 months. For renal cell carcinoma, time to next treatment was recorded manually for all patients.Statistical analysis was performed in R using the survival package. Graph-Pad Prism was used for basic analysis and generating graphs.Additional information can be found in the Life Sciences Reporting Summary.
Samstein R.M., Lee C.H., Shoushtari A.N., Hellmann M.D., Shen R., Janjigian Y.Y., Barron D.A., Zehir A., Jordan E.J., Omuro A., Kaley T.J., Kendall S.M., Motzer R.J., Hakimi A.A., Voss M.H., Russo P., Rosenberg J., Iyer G., Bochner B.H., Bajorin D.F., Al-Ahmadie H.A., Chaft J.E., Rudin C.M., Riely G.J., Baxi S., Ho A.L., Wong R.J., Pfister D.G., Wolchok J.D., Barker C.A., Gutin P.H., Brennan C., Tabar V., Mellinghoff I.K., DeAngelis L.M., Ariyan C.E., Lee N., Tap W.D., Gounder M.M., D’Angelo S.P., Saltz L., Stadler Z.K., Scher H.I., Baselga J., Razavi P., Klebanoff C.A., Yaeger R., Segal N.H., Ku G.Y., DeMatteo R.P., Ladanyi M., Rizvi N.A., Berger M.F., Riaz N., Solit D.B., Chan T.A, & Morris L.G. (2019). Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature genetics, 51(2), 202-206.
Publication 2019
Cancer of Head and Neck Diploid Cell Disease Progression Exons Malignant Neoplasms Mutation Neoplasms Non-Small Cell Lung Carcinoma Oncogenes Patients Pharmaceutical Preparations Pharmacotherapy prisma Renal Cell Carcinoma X-Rays, Diagnostic
4
Colorectal Cancer Patient Cohort Analysis
Cited 76 times
The French national Cartes d'Identité des Tumeurs (CIT) program involves a multicenter cohort of 750 patients with stage I to IV CC who underwent surgery between 1987 and 2007 in seven centers. Fresh-frozen primary tumor tissue samples were retrospectively collected at the Institut Gustave Roussy (Villejuif), the Hôpital Saint Antoine (Paris), the Hôpital Européen Georges Pompidou (Paris), the Hôpital de Hautepierre (Strasbourg), the Hôpital Purpan (Toulouse), and the Institut Paoli-Calmettes (Marseille), and prospectively collected at the Centre Antoine Lacassagne (Nice). Patients who received preoperative chemotherapy and/or radiation therapy and those with primary rectal cancer were excluded from this study. Clinical and pathologic data were extracted from the medical records and centrally reviewed for the purpose of this study. Patients were staged according to the American Joint Committee on Cancer tumor node metastasis (TNM) staging system [2] and monitored for relapse (distant and/or locoregional recurrence; median follow-up of 51.5 mo). Patient and tumor characteristics are summarized in Table 1 and detailed in Table S1.
Of the 750 tumor samples of the CIT cohort, 566 fulfilled RNA quality requirements for GEP analysis (Figure S1). The 566 samples were split into a discovery set (n = 443) and a validation set (n = 123), well balanced for the main anatomoclinical characteristics (Table 1). The validation set also included 906 CC samples available from seven public datasets (GSE13067, GSE13294, GSE14333, GSE17536/17537, GSE18088, GSE26682, and GSE33113). These datasets corresponded to all available public datasets fulfilling the following criteria: available GEP data obtained using a similar chip platform (Affymetrix U133 Plus 2.0 chips) with raw data CEL files, and tumor location and either common DNA alteration (n = 457) and/or patient outcome (n = 449) data available. Within the discovery (n = 443) and the validation (n = 1,029) sets, 359 and 416 patients with stage II–III CC and documented relapse-free survival (RFS) were available for survival analysis, respectively (Figure S1). The dataset from The Cancer Genome Atlas (TCGA) [13] (link), although obtained using a non-Affymetrix platform and therefore analyzed separately, was added to the validation set because of the extensive DNA alteration annotations provided for 152 CC samples.
Marisa L., de Reyniès A., Duval A., Selves J., Gaub M.P., Vescovo L., Etienne-Grimaldi M.C., Schiappa R., Guenot D., Ayadi M., Kirzin S., Chazal M., Fléjou J.F., Benchimol D., Berger A., Lagarde A., Pencreach E., Piard F., Elias D., Parc Y., Olschwang S., Milano G., Laurent-Puig P, & Boige V. (2013). Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value. PLoS Medicine, 10(5), e1001453.
Full text: Click here
Publication 2013
DNA Chips Freezing Genome Joints Malignant Neoplasms Neoplasm Metastasis Neoplasms Neoplasms by Site Operative Surgical Procedures Patients Pharmacotherapy Radiotherapy Rectal Cancer Recurrence Relapse Tissues
5
Systematic Review of Geriatric Medication Safety
Cited 76 times
The literature from December 1, 2001 (the end of the previous panel's search) to March 30, 2011, was searched to identify published systematic reviews and meta-analyses that were relevant to the project. Search terms included adverse drug reactions, adverse drug events, medication problems, polypharmacy, inappropriate drug use, suboptimal drug therapy, drug monitoring, pharmacokinetics, drug interactions, and medication errors. Terms were searched alone and in combination. Search limits included human subjects, English language, and aged 65 and older. Data sources for the initial search included Medline, the Cochrane Library (Cochrane Database of Systematic Reviews), International Pharmaceutical abstracts, and references lists of selected articles that the panel co-chairs identified.
The initial search identified 25,549 citations, of which 6,505 were selected for preliminary review. The panel co-chairs reviewed 2,267 citations, of which 844 were excluded for not meeting the study purpose or not containing primary data. An additional search was conducted with the additional terms drug–drug and drug–disease interactions, pharmacoepidemiology, drug safety, geriatrics, and elderly prescribing. An additional search for randomized clinical trials and postmarketing and observational studies published between 2009 and 2011 was conducted using terms related to major drug classes and conditions, delimited by more-general topics (e.g., adverse drug reactions, Beers Criteria, suboptimal prescribing, and interventions). Previous searches were used to develop additional terms to be included in subsequent searches, such as a list of authors whose work was relevant to the goals of the project. When evidence was sparse on older medications, searches were conducted on drug class and individual medication names and included older search dates for these drugs. The co-chairs continually reviewed the updated search results for articles that might be relevant to the project. Panelists were also asked to forward pertinent citations that might be useful for revising the previous Beers Criteria or supporting additions to them.
At the time of the panel's face-to-face meeting, the co-chairs had selected 2,169 unduplicated citations for the full panel review. This total included 446 systematic reviews or meta-analyses, 629 randomized controlled trials, and 1,094 observational studies. Additional articles were found in a manual search of the reference lists of identified articles and the panelist's files, book chapter, and recent review articles, with 258 citations selected for the final evidence tables to support the list of drugs to avoid.
, & Campanelli C.M. (2012). American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults: The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. Journal of the American Geriatrics Society, 60(4), 616-631.
Publication 2012
Aged cDNA Library Drug Interactions Drug Kinetics Drug Reaction, Adverse Drugs, Non-Prescription Face Pharmaceutical Preparations Pharmacotherapy Polypharmacy Safety

Most recents protocols related to «Pharmacotherapy»

1
Treatment of Pediatric Wilms Tumor
Not available on PMC !

Example 9

A pediatric patient with Stage IV Wilms tumor is treated with dactinomycin, doxorubicin, cyclophosphamide and vincristine for 65 weeks. Doses of the drugs are as follows: dactinomycin (15 mcg/kg/d [IV]), vincristine (1.5 mg/m 2 wk [IV)), Adriamycin (doxorubicin 20 mg/m2/d [IV]), and cyclophosphamide (10 mg/kg/d [IV]). Dactinomycin courses are given postoperatively and at 13, 26, 39, 52, and 65 weeks. Vincristine is given on days 1 and 8 of each Adriamycin course. Adriamycin is given for three daily doses at 6, 19, 32, 45, and 58 weeks. Cyclophosphamide is given for three daily doses during each Adriamycin and each dactinomycin course except the postoperative dactinomycin course. During each administration of dactinomycin and vincristine a dose of 0.2 cc/kg of DDFPe is administered while the patient breathes supplemental oxygen. *D'angio, Giulio J., et al. “Treatment of Wilms' tumor. Results of the third national Wilms' tumor study.” Cancer 64.2 (1989): 349-360.

US11857627B2. Fractionated radiotherapy and chemotherapy with an oxygen therapeutic (2024-01-02). NuvOx Pharma LLC [US]. Inventors: Evan C. Unger [US].
Full text: Click here
Patent 2024
Adriamycin Cyclophosphamide Dactinomycin Doxorubicin Malignant Neoplasms Nephroblastoma Oxygen Patients Pharmaceutical Preparations Pharmacotherapy Radiotherapy Vincristine
2
Enhancing Rhabomyosarcoma Treatment
Not available on PMC !

Example 6

An adult patient with rhabomyosarcoma is treated with IV Vincristine at a dose of 1.4 mg/m2. Concomitantly the patient is administered 0.1 cc kg of DDFPc while breathing room air. Despite breathing room air, increased oxygen levels am still attained in the tumor tissue resulting in increased activity of the drug.

US11857627B2. Fractionated radiotherapy and chemotherapy with an oxygen therapeutic (2024-01-02). NuvOx Pharma LLC [US]. Inventors: Evan C. Unger [US].
Full text: Click here
Patent 2024
Adult Neoplasms Oxygen Patients Pharmaceutical Preparations Pharmacotherapy Radiotherapy Therapeutics Tissues Vincristine
3
Prostate Cancer Biomarker Monitoring
Not available on PMC !

Example 3

At the time of diagnosis with prostate cancer, subjects are invited to participate in a trial. A subject sample, e.g., blood, is obtained. Periodically, throughout the monitoring, watchful waiting, or active treatment of the subject, e.g., chemotherapy, radiation therapy, e.g., radiation of the prostate, surgery, e.g., surgical prostate resection, hormone therapy, a new subject sample is obtained. At the end of the study, all subject samples are tested for the level of FLNA and/or PSA, and optionally other markers. The subject samples are matched to the medical records of the subjects to correlate FLNA and/or PSA levels, as appropriate, with prostate cancer status at the time of diagnosis, rate of progression of disease, response of subjects to one or more interventions, and transitions between androgen dependent and independent status. Other markers, such as the expression level of keratin 19 and/or filamin B, the age of the subjects, or the prostate volume of the subjects, can also be analyzed in addition to filamin A and/or PSA.

US11866487B2. Filamin A binding proteins and uses thereof (2024-01-09). BPGbio, Inc. [US]. Inventors: Wenfang Sybil Wu [US], Shobha Ravipaty [US], Tracey Friss [US], Viatcheslav R. Akmaev [US], Nikunj Narendra Tanna [US].
Full text: Click here
Patent 2024
Androgens BLOOD Diagnosis Disease Progression Filamin A Filamin B Hormones Keratin-19 Operative Surgical Procedures Pharmacotherapy Prostate Prostate Cancer Prostatectomy Radiotherapy Therapeutics
4
Cervical Cancer Chemoradiation with NVX-108
Not available on PMC !

Example 3

A female patient with cervical carcinoma is treated with combined radiation therapy and chemotherapy+NVX-108. Radiation dosage is 45 Gray (Gy) in 20 fractions followed by low dose-rate intracavitary application of 30 Gy to the cervical region. Chemotherapy consists of intravenous cisplatin 40 mg/m2 every week for up to 6 weekly cycles. The patient is administered a bolus IV dose of 0.2 cc/kg NVX-108 (2% w/vol DDFPe) 60 minutes prior to each dose of radiation. Follow-up shows complete response to treatment.

US11857627B2. Fractionated radiotherapy and chemotherapy with an oxygen therapeutic (2024-01-02). NuvOx Pharma LLC [US]. Inventors: Evan C. Unger [US].
Full text: Click here
Patent 2024
Cervical Cancer Cisplatin Neck NVX-108 Oxygen Patients Pharmacotherapy Radiotherapy Woman
5
Myeloma Treatment with Carmustine and DDFP
Not available on PMC !

Example 7

A patient with multiple myeloma is treated with BiCNU® (carmustine for injection), a nitrosourea (1,3-bis(2-chloroethyl)-1-nitrosourea) in combination with prednisone. The dose of BiCNU administered to this previously untreated patient is 200 mg/m2 intravenously every 6 weeks. This is divided into daily injections of 100 mg/m2 on 2 successive days. DDFPe is administered as an IV bolus (dose=0.2 cc/kg, 2% w/vol DDFP) during each dose of BiCNU while the patient breathes supplemental oxygen for 60 minutes. A repeat course of BiCNU is again administered once the circulating blood elements have returned to acceptable levels (platelets above 100,000/mm3, leukocytes above 4,000/mm3), in 6 weeks, and again DDFPe is administered concomitantly with BiCNU.

US11857627B2. Fractionated radiotherapy and chemotherapy with an oxygen therapeutic (2024-01-02). NuvOx Pharma LLC [US]. Inventors: Evan C. Unger [US].
Full text: Click here
Patent 2024
BiCNU Blood Component Transfusion Blood Platelets Carmustine Leukocytes Multiple Myeloma Nitrosourea Compounds Oxygen Patients Pharmacotherapy Prednisone Radiotherapy Therapeutics

Top products related to «Pharmacotherapy»

1
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
2
Sas version 9 by SAS Institute
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
3
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
4
Rpmi 1640 medium by Thermo Fisher Scientific
Sourced in United States, China, Germany, United Kingdom, Japan, France, Canada, Australia, Italy, Switzerland, Belgium, New Zealand, Spain, Israel, Sweden, Denmark, Macao, Brazil, Ireland, India, Austria, Netherlands, Holy See (Vatican City State), Poland, Norway, Cameroon, Hong Kong, Morocco, Singapore, Thailand, Argentina, Taiwan, Province of China, Palestine, State of, Finland, Colombia, United Arab Emirates
RPMI 1640 medium is a commonly used cell culture medium developed at Roswell Park Memorial Institute. It is a balanced salt solution that provides essential nutrients, vitamins, and amino acids to support the growth and maintenance of a variety of cell types in vitro.
5
Dulbecco modified eagle medium (dmem) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
6
Rpmi 1640 by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, France, Canada, Japan, Australia, Italy, Switzerland, Belgium, New Zealand, Austria, Netherlands, Israel, Sweden, Denmark, India, Ireland, Spain, Brazil, Norway, Argentina, Macao, Poland, Holy See (Vatican City State), Mexico, Hong Kong, Portugal, Cameroon
RPMI 1640 is a common cell culture medium used for the in vitro cultivation of a variety of cells, including human and animal cells. It provides a balanced salt solution and a source of essential nutrients and growth factors to support cell growth and proliferation.
7
Cisplatin by Merck Group
Sourced in United States, Germany, United Kingdom, China, Sao Tome and Principe, Macao, Italy, France, Canada, Japan, Spain, Czechia, Poland, Australia, India, Switzerland, Sweden, Belgium, Portugal
Cisplatin is a platinum-based medication used as a chemotherapeutic agent. It is a crystalline solid that can be dissolved in water or saline solution for administration. Cisplatin functions by interfering with DNA replication, leading to cell death in rapidly dividing cells.
8
Penicillin streptomycin by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
9
Prism 8 by GraphPad
Sourced in United States, Austria, Canada, Belgium, United Kingdom, Germany, China, Japan, Poland, Israel, Switzerland, New Zealand, Australia, Spain, Sweden
Prism 8 is a data analysis and graphing software developed by GraphPad. It is designed for researchers to visualize, analyze, and present scientific data.

More about "Pharmacotherapy"

Pharmacotherapy, also known as drug therapy or medication management, is a crucial aspect of healthcare that involves the use of pharmacological agents to treat and manage various medical conditions.
This comprehensive approach to patient care encompasses the selection, dosing, and administration of drugs to achieve the desired therapeutic effects while minimizing adverse reactions.
Effective pharmacotherapy requires a deep understanding of pharmacokinetics (the movement of drugs within the body) and pharmacodynamics (the effects of drugs on the body).
Healthcare professionals, such as physicians, pharmacists, and nurses, work collaboratively to develop personalized treatment plans, considering factors like age, comorbidities, and genetic factors.
The field of pharmacotherapy is constantly evolving, with new medications and therapies being developed to address unmet medical needs.
From chronic conditions like hypertension and diabetes to acute illnesses and infectious diseases, pharmacotherapy plays a vital role in improving patient outcomes and quality of life.
PubCompare.ai, a revolutionary AI-powered platform, can assist researchers in optimizing pharmacotherapy protocols by providing access to a vast database of literature, preprints, and patents.
This cutting-edge technology allows users to easily locate and compare various protocols, leveraging advanced AI algorithms to identify the best solutions for their needs.
Whether you're a healthcare provider, researcher, or pharmaceutical professional, understanding the principles of pharmacotherapy is essential for delivering effective and safe patient care.
By staying up-to-date with the latest advancements in this dynamic field, you can make informed decisions and contribute to the ongoing progress in the treatment and management of a wide range of medical conditions.